Sacral Nerve Stimulation at Subsensory Threshold Does Not Compromise Treatment Efficacy Results From a Randomized, Blinded Crossover Study

被引:28
|
作者
Duelund-Jakobsen, Jakob [1 ]
Buntzen, Steen [1 ]
Lundby, Lilli [1 ]
Laurberg, Soren [1 ]
机构
[1] Aarhus Univ Hosp, Dept Surg P, Surg Res Unit, DK-8000 Aarhus C, Denmark
关键词
fecal incontinence; idiopathic fecal incontinence; patient satisfaction; sacral nerve stimulation; sensory threshold; stimulation amplitude; QUALITY-OF-LIFE; FECAL INCONTINENCE; ELECTRICAL-STIMULATION; ANAL INCONTINENCE; NEUROMODULATION; CONSTIPATION; PREVALENCE; MODULATION; ACTIVATION; EXPERIENCE;
D O I
10.1097/SLA.0b013e318269d493
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background and Objective: Stimulation amplitude used in sacral nerve stimulation (SNS) is at or just above the sensory threshold (ST). This randomized, blinded crossover study aimed to document if stimulation at 75% or 50% of the ST would be as effective as stimulation at the ST for fecal incontinence (FI). Method: FI patients treated with SNS, who were satisfied with current treatment results and had a minimum symptom reduction of 75%, were eligible. Patients were randomized into 3 periods of 4-week stimulation: ST, 75% of the ST, and 50% of the ST. Patients completed a bowel habit diary and questionnaires on bowel functions and patient satisfaction at the study baseline and in each study period. Results: Nineteen patients (18 females) with a mean follow-up of 51.7 +/- 29.9 months were included from January to April 2010. The mean FI episodes per 3 weeks decreased from pre-SNS therapy 33.6 +/- 31.6 to 1.1 +/- 2.2 at the study baseline (P < 0.001). Decreasing the stimulation amplitude to as low as 50% of the ST did not affect the overall number of incontinent episodes (P = 0.078). The Wexner incontinence score dropped from 16.5 +/- 2.5 for pre-SNS therapy to 7.4 +/- 3.1 at the study baseline (P < 0.001). Decreasing the stimulation amplitude to ST, 75% of the ST or 50% of the ST, did not change the Wexner score when compared with the study baseline (P = 0.581). In general, patient satisfaction was high at the study baseline and did not deteriorate as the stimulation amplitude was decreased to 50% of the ST (P = 0.932). Conclusions: Subsensory stimulation as low as 50% of the ST is as effective as stimulation at or above the ST. The study was approved by the Regional Committee on Biomedical Research Ethics, Denmark, and registered at ClinicalTrials.gov (NCT01130870).
引用
收藏
页码:219 / 223
页数:5
相关论文
共 38 条
  • [31] The Efficacy and Safety of Deep Brain Stimulation of Combined Anterior Limb of Internal Capsule and Nucleus Accumbens (ALIC/NAcc-DBS) for Treatment-Refractory Obsessive-Compulsive Disorder: Protocol of a Multicenter, Randomized, and Double-Blinded Study
    Xu, Tingting
    Gao, Yuan
    Li, Bin
    Jiang, Jiaxin
    Guo, Huirong
    Liu, Xianzhi
    Huang, Hongxing
    Cheng, Yuqi
    Yu, Hualin
    Hu, Jie
    Wu, Xi
    Wang, Wei
    Wang, Zhen
    BRAIN SCIENCES, 2022, 12 (07)
  • [32] Does an Age-Specific Treatment Program Augment the Efficacy of a Cognitive-Behavioral Weight Loss Program in Adolescence and Young Adulthood? Results from a Controlled Study
    Warschburger, Petra
    Zitzmann, Jana
    NUTRIENTS, 2019, 11 (09)
  • [33] Efficacy and safety of secondary prophylactic vs. on-demand sucrose-formulated recombinant factor VIII treatment in adults with severe hemophilia A: results from a 13-month crossover study
    Collins, P.
    Faradji, A.
    Morfini, M.
    Enriquez, M. M.
    Schwartz, L.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2010, 8 (01) : 83 - 89
  • [34] Transcutaneous vagus nerve stimulation (t-VNS): A novel effective treatment for temper outbursts in adults with Prader-Willi Syndrome indicated by results from a non-blind study
    Manning, Katherine E.
    Beresford-Webb, Jessica A.
    Aman, Lucie C. S.
    Ring, Howard A.
    Watson, Peter C.
    Porges, Stephen W.
    Oliver, Chris
    Jennings, Sally R.
    Holland, Anthony J.
    PLOS ONE, 2019, 14 (12): : e0223750
  • [35] Long-term efficacy and safety of migalastat treatment in Fabry disease: 30-month results from the open-label extension of the randomized, phase 3 ATTRACT study
    Feldt-Rasmussen, Ulla
    Hughes, Derralynn
    Sunder-Plassmann, Gere
    Shankar, Suma
    Nedd, Khan
    Olivotto, Iacopo
    Ortiz, Damara
    Ohashi, Toya
    Hamazaki, Takashi
    Skuban, Nina
    Yu, Julie
    Barth, Jay A.
    Nicholls, Kathleen
    MOLECULAR GENETICS AND METABOLISM, 2020, 131 (1-2) : 219 - 228
  • [36] A post hoc analysis of migraine-associated symptoms from the phase 3 randomized, double-blind, sham-controlled Trial of External trigeminal nerve stimulation for the Acute treatment of Migraine (TEAM) study
    Panza, Gregory A.
    Johnson, Michael A. L.
    Kuruvilla, Deena E.
    HEADACHE, 2024, : 779 - 790
  • [37] Efficacy and safety of tedizolid for the treatment of ventilated gram-positive hospital-acquired or ventilator-associated bacterial pneumonia in Japanese patients: Results from a subgroup analysis of a phase 3, randomized, double-blind study comparing tedizolid and linezolid
    Mikamo, Hiroshige
    Nagashima, Makoto
    Kusachi, Shinya
    Fujimi, Satoshi
    Oshima, Nobuyuki
    De Anda, Carisa
    Takase, Akiko
    JOURNAL OF INFECTION AND CHEMOTHERAPY, 2022, 28 (09) : 1235 - 1241
  • [38] Efficacy and safety of mirogabalin for the treatment of fibromyalgia: results from three 13-week randomized, double-blind, placebo- and active-controlled, parallel-group studies and a 52-week open-label extension study
    Arnold, Lesley M.
    Whitaker, Susan
    Hsu, Ching
    Jacobs, David
    Merante, Domenico
    CURRENT MEDICAL RESEARCH AND OPINION, 2019, 35 (10) : 1825 - 1835